LATE GRAFT LOSS AFTER KIDNEY TRANSPLANTATION: IS "DEATH WITH FUNCTION" REALLY DEATH WITH A FUNCTIONING ALLOGRAFT?
About half of late kidney allograft losses are attributed to death with function (DWF), a poorly-characterized outcome. An ongoing question is whether "DWF" is a consequence of chronic allograft dysfunction. Using the prospective DeKAF database, we sought to better define the impact, phenotype, and clinical course of DWF in the current era. 3587 kidney recipients with functional grafts at 90 days posttransplant were followed prospectively for a median of 5.4 years. Characteristics at transplantation in those with DWF (N=350, 9.8%) differed from those who otherwise lost their grafts (DC-GF, N=295, 8.2%) or maintained function (MF, N=2942, 82.0%); DWF patients were older, sicker, had been on dialysis longer, with more preexisting cardiovascular disease. While DC-GF patients experienced more early rejection, more acute rejection after 90 days, and a clinically-significant decrease in kidney function prior to graft failure. In contrast, the clinical course after transplantation in DWF patients did not differ prior to death from those who maintained function throughout. DWF and DC-GF in kidney transplant recipients represent differing clinical phenotypes occurring in distinct patient populations. Reducing the impact of DWF requires better definition of causes and clinical course and then trials of therapies to improve outcomes. Composite endpoints in clinical trials that group DWF and DC-GF together may obscure important clinical findings.